Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation
Open Access
- 1 June 2016
- journal article
- research article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 22 (6), 1030-1036
- https://doi.org/10.1016/j.bbmt.2016.02.004
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemiaLeukemia, 2013
- Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemiaBlood, 2012
- Has MRD monitoring superseded other prognostic factors in adult ALL?Blood, 2012
- High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessmentProceedings of the National Academy of Sciences of the United States of America, 2011
- Autologous hematopoietic cell transplantation for high-risk ALLBone Marrow Transplantation, 2010
- Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant ResearchBone Marrow Transplantation, 2007
- Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaBlood, 2006
- Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Blood, 2005
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998